Active pharmaceutical ingredients (API) company MSN Labs, the parent company of Novadoz Pharmaceuticals, reported on Monday the receipt of US FDA approval to market Abiraterone Acetate 250mg tablets in 120 tablet count bottles for the treatment of prostate cancer with a steroid medication (prednisone or methylprednisolone).
This US FDA approval marks the ninth since March 2018, when Novadoz began commercial operations as MSN Labs' US sales and marketing affiliate for their finished dosage forms.The company expects additional product launches over the next 12 months continuing the organization's meteoric entrance and rise in the US market.
Additionally, the Abiraterone Acetate 250mg tablets is the second oncology product launched by Novadoz.
The company added that the Abiraterone Acetate 250mg tablets are the generic version of Janssen Pharmaceuticals' product Zytiga.
Civica Rx, Hikma to Ship Heparin and Seven Other Essential Injectable Medicines
US FDA grants approval to Meitheal Pharmaceuticals' Enoxaparin Sodium Injection
BioDuro names Dr Kent Payne as president of Global CMC Solutions
US FDA Approves Amneal ANDA for Generic Carafate
Dr Reddy's Laboratories reports availability of Deferasirox Tablets for oral suspension in US market
Amneal Launches Generic Revatio for Oral Suspension and Generic Amicar Tablets
Dr Reddy's Laboratories unveils Bortezomib for Injection 3.5 mg/vial in the US
Breckenridge wins FDA final approval for Rivastigmine Transdermal System ANDA
Amneal to unveil generic Revatio and Amicar Tablets in the US market